<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953927</url>
  </required_header>
  <id_info>
    <org_study_id>C-020-485</org_study_id>
    <secondary_id>Oxford TB020</secondary_id>
    <nct_id>NCT00953927</nct_id>
  </id_info>
  <brief_title>A Study of MVA85A in Healthy Infants</brief_title>
  <official_title>Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aeras</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity
      and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without
      tuberculosis or HIV infection. This study planned to enroll 2784 infants (126 to 182 days of
      age) who received study vaccine or control and were followed for 15 - 36 months. The study
      was conducted at a single site in South Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity
      and efficacy of MVA85A/AERAS-485 in BCG vaccinated infants without tuberculosis or HIV
      infection. Infants (126 to 182 days) received intradermal (ID) study vaccine
      (MVA85A/AERAS-485 or Candida skin test antigen control). All infants were to be followed for
      at least 15 months after the last infant was enrolled into the study. Given completion of
      enrollment in 21 months, the total duration of follow-up for each infant was scheduled to be
      at least 15 months and up to 36 months. Infants were to be followed for the entire duration
      of the study both for the development of tuberculosis and serious adverse events.

      On enrollment to the study, eligible infants were assigned to a study group starting with
      Study Group 1 and were randomized in a 1:1 ratio within a study group to receive either
      MVA85A/AERAS-485 or Candida skin test antigen control. Infants were assigned to a safety
      cohort (Study Group 1), then into 1 of 3 immunological assay evaluation groups (Study Groups
      2-4), and finally the remainder of infants were assigned into the correlate of protection
      cohort (Study Group 5). At least 330 infants were to be randomized in Study Group 1, up to
      50-60 infants each in Study Groups 2-4, and the remaining infants were randomized in Study
      Group 5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants.</measure>
    <time_frame>AEs recorded 28 days post-vaccination; SAEs recorded for entire study period.</time_frame>
    <description>Adverse events (AE) were collected for 28 days after vaccination. The subject's parent or guardian recorded information regarding occurrences of solicited adverse events in diary cards through 7 days after vaccination. Serious adverse events (SAE) were collected from the time of study vaccine dosing throughout the entire study. A safety cohort (the first 330 infants enrolled) also had serum chemistry and hematology testing up to 28 days post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants.</measure>
    <time_frame>15 to 36 months post-vaccination</time_frame>
    <description>The number (percentage) of subjects with a diagnosis of tuberculosis based on clinically-derived tuberculosis (TB) diagnostic criteria were summarized by treatment group for all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells.</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>Intracellular cytokine staining (ICS) assay immune response was expressed as the percentage of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells producing any one of three cytokines (IFN-γ, TNF-α, or IL-2) or any combination of the three cytokines simultaneously after stimulation with an Ag85A peptide pool on a subset of infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials.</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>An ex vivo IFN-γ ELISPOT assay was used to assess specific T cell responses to an Ag85A peptide pool for a subset of infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay.</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>Frequencies of CD4 and CD8 T cells expressing cytokines (IFN-γ, IL-2 and TNF-α) following stimulation of whole blood with an Ag85A peptide pool were also measured by flow cytometry for a subset of infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Discover Correlates of Protection From Tuberculosis in Infants Vaccinated With MVA85A/AERAS-485.</measure>
    <time_frame>15 to 36 months post-vaccination</time_frame>
    <description>Investigations for determining correlates of immune protection to TB will not be completed as planned because the study did not show TB protection in MVA85A/AERAS-485 recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.</measure>
    <time_frame>15 to 36 months post-vaccination</time_frame>
    <description>The number (percentage) of infants with QuantiFERON conversions at any time on the study were summarized by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2797</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Investigational Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA85A/AERAS-485</intervention_name>
    <description>Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10^8 pfu.</description>
    <arm_group_label>Investigational Vaccine</arm_group_label>
    <other_name>Manufactured by IDT of Germany.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Candida Skin Test Antigen</intervention_name>
    <description>1 test, administered once as a placebo control.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Candin(R)</other_name>
    <other_name>Manufactured by Allermed Laboratories of USA.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 126 through 182 days on the day of randomization (Study Day 0)

          2. Written informed consent obtained from the parents/guardian

          3. Weight: by chart &gt;3rd percentile on Study Day 0 or, if &lt; 3rd percentile, infant has
             shown a stable growth pattern

          4. BCG vaccination within 7 days of birth

          5. Generally good health confirmed by medical history and physical examination within 35
             days prior to Study Day 0

          6. Must have received age-appropriate doses of pneumococcal vaccine as recommended by the
             South African Department of Health but no injection within 14 day prior to Study Day 0

          7. Ability to complete follow-up period as required by the protocol

          8. Completed simultaneous enrollment in the Aeras Vaccine Development Registry protocol

        Exclusion Criteria:

          1. Acute illness on Study Day 0

          2. Fever &gt;=37.5 degrees Celsius on Study Day 0

          3. Evidence of significant active infection on Study Day 0

          4. Received a Expanded Program of Immunization (EPI) within 14 days prior to Study Day 0

          5. Historical or virological evidence of individual or maternal human immunodeficiency
             virus (HIV-1) infection

          6. History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccine

          7. Previous medical history, or evidence, of an intercurrent illness that may compromise
             the safety of the infant in the study

          8. Evidence of chronic hepatitis from any cause

          9. History or evidence of any systemic disease on physical examination or any acute,
             chronic or intercurrent illness that, in the opinion of the investigator, may
             interfere with the evaluation of the safety or immunogenicity of the vaccine

         10. History of or known tuberculosis or treatment for tuberculosis

         11. Shared residence since birth with an individual with active tuberculosis or on
             anti-tuberculosis treatment for less than 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>126 Days</minimum_age>
    <maximum_age>182 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Tameris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South African Tuberculosis Vaccine Initiative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Landry, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Aeras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen McShane, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oxford; Centre for Vaccinology &amp; Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative (Satellite)</name>
      <address>
        <city>Ceres</city>
        <zip>6835</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative (Satellite)</name>
      <address>
        <city>Robertson</city>
        <zip>6705</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative (Headquarters)</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021-8.</citation>
    <PMID>23391465</PMID>
  </reference>
  <reference>
    <citation>Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill M, Mahomed H. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis (Edinb). 2013 Mar;93(2):143-9. doi: 10.1016/j.tube.2013.01.003. Epub 2013 Feb 12.</citation>
    <PMID>23410889</PMID>
  </reference>
  <reference>
    <citation>Mulenga H, Tameris MD, Luabeya KK, Geldenhuys H, Scriba TJ, Hussey GD, Mahomed H, Landry BS, Hanekom WA, McShane H, Hatherill M. The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children. Pediatr Infect Dis J. 2015 Nov;34(11):1157-62. doi: 10.1097/INF.0000000000000847.</citation>
    <PMID>26226446</PMID>
  </reference>
  <reference>
    <citation>Luabeya KK, Tameris MD, Geldenhuys HD, Mulenga H, Van Schalkwyk A, Hughes EJ, Toefey A, Scriba TJ, Hussey G, Mahomed H, McShane H, Landry B, Hanekom WA, Hatherill M. Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatr Infect Dis J. 2015 Nov;34(11):1218-22. doi: 10.1097/INF.0000000000000874.</citation>
    <PMID>26252568</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>October 23, 2013</results_first_submitted>
  <results_first_submitted_qc>October 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2013</results_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Investigational Vaccine</title>
          <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1399"/>
                <participants group_id="P2" count="1398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1294"/>
                <participants group_id="P2" count="1303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other study discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population</population>
      <group_list>
        <group group_id="B1">
          <title>Investigational Vaccine</title>
          <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1399"/>
            <count group_id="B2" value="1398"/>
            <count group_id="B3" value="2797"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1399"/>
                    <measurement group_id="B2" value="1398"/>
                    <measurement group_id="B3" value="2797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".401" spread=".039"/>
                    <measurement group_id="B2" value=".399" spread=".037"/>
                    <measurement group_id="B3" value=".400" spread=".038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="691"/>
                    <measurement group_id="B2" value="682"/>
                    <measurement group_id="B3" value="1373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="708"/>
                    <measurement group_id="B2" value="716"/>
                    <measurement group_id="B3" value="1424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1399"/>
                    <measurement group_id="B2" value="1398"/>
                    <measurement group_id="B3" value="2797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants.</title>
        <description>Adverse events (AE) were collected for 28 days after vaccination. The subject's parent or guardian recorded information regarding occurrences of solicited adverse events in diary cards through 7 days after vaccination. Serious adverse events (SAE) were collected from the time of study vaccine dosing throughout the entire study. A safety cohort (the first 330 infants enrolled) also had serum chemistry and hematology testing up to 28 days post-vaccination.</description>
        <time_frame>AEs recorded 28 days post-vaccination; SAEs recorded for entire study period.</time_frame>
        <population>All subjects vaccinated.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants.</title>
          <description>Adverse events (AE) were collected for 28 days after vaccination. The subject's parent or guardian recorded information regarding occurrences of solicited adverse events in diary cards through 7 days after vaccination. Serious adverse events (SAE) were collected from the time of study vaccine dosing throughout the entire study. A safety cohort (the first 330 infants enrolled) also had serum chemistry and hematology testing up to 28 days post-vaccination.</description>
          <population>All subjects vaccinated.</population>
          <units>percentage of all subjects vaccinated</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1399"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="94.7" upper_limit="96.8"/>
                    <measurement group_id="O2" value="83.7" lower_limit="81.7" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants.</title>
        <description>The number (percentage) of subjects with a diagnosis of tuberculosis based on clinically-derived tuberculosis (TB) diagnostic criteria were summarized by treatment group for all subjects.</description>
        <time_frame>15 to 36 months post-vaccination</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants.</title>
          <description>The number (percentage) of subjects with a diagnosis of tuberculosis based on clinically-derived tuberculosis (TB) diagnostic criteria were summarized by treatment group for all subjects.</description>
          <population>Per protocol population</population>
          <units>participants with a diagnosis of TB</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1399"/>
                <count group_id="O2" value="1395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells.</title>
        <description>Intracellular cytokine staining (ICS) assay immune response was expressed as the percentage of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells producing any one of three cytokines (IFN-γ, TNF-α, or IL-2) or any combination of the three cytokines simultaneously after stimulation with an Ag85A peptide pool on a subset of infants.</description>
        <time_frame>28 days post-vaccination</time_frame>
        <population>Pre-specified population subset</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells.</title>
          <description>Intracellular cytokine staining (ICS) assay immune response was expressed as the percentage of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells producing any one of three cytokines (IFN-γ, TNF-α, or IL-2) or any combination of the three cytokines simultaneously after stimulation with an Ag85A peptide pool on a subset of infants.</description>
          <population>Pre-specified population subset</population>
          <units>percentage of cytokine expressing cells</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent cytokine expressing CD4 cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" lower_limit="0.003" upper_limit="0.038"/>
                    <measurement group_id="O2" value="0.003" lower_limit="0.000" upper_limit="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent cytokine expressing CD8 cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="0.000" upper_limit="0.011"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials.</title>
        <description>An ex vivo IFN-γ ELISPOT assay was used to assess specific T cell responses to an Ag85A peptide pool for a subset of infants.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>Pre-specified population subset</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials.</title>
          <description>An ex vivo IFN-γ ELISPOT assay was used to assess specific T cell responses to an Ag85A peptide pool for a subset of infants.</description>
          <population>Pre-specified population subset</population>
          <units>SFC per million PBMCs</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.000" lower_limit="107.000" upper_limit="295.350"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.000" upper_limit="2.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay.</title>
        <description>Frequencies of CD4 and CD8 T cells expressing cytokines (IFN-γ, IL-2 and TNF-α) following stimulation of whole blood with an Ag85A peptide pool were also measured by flow cytometry for a subset of infants.</description>
        <time_frame>28 days post-vaccination</time_frame>
        <population>Pre-specified population subset</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay.</title>
          <description>Frequencies of CD4 and CD8 T cells expressing cytokines (IFN-γ, IL-2 and TNF-α) following stimulation of whole blood with an Ag85A peptide pool were also measured by flow cytometry for a subset of infants.</description>
          <population>Pre-specified population subset</population>
          <units>percentage of cytokine expressing cells</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent IL2/IFN-gamma/TNF expressing CD4 cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" lower_limit="0.022" upper_limit="0.079"/>
                    <measurement group_id="O2" value="0.001" lower_limit="0.000" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent IL2/IFN-gamma/ TNF expressing CD8 cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Discover Correlates of Protection From Tuberculosis in Infants Vaccinated With MVA85A/AERAS-485.</title>
        <description>Investigations for determining correlates of immune protection to TB will not be completed as planned because the study did not show TB protection in MVA85A/AERAS-485 recipients.</description>
        <time_frame>15 to 36 months post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Discover Correlates of Protection From Tuberculosis in Infants Vaccinated With MVA85A/AERAS-485.</title>
          <description>Investigations for determining correlates of immune protection to TB will not be completed as planned because the study did not show TB protection in MVA85A/AERAS-485 recipients.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.</title>
        <description>The number (percentage) of infants with QuantiFERON conversions at any time on the study were summarized by treatment group.</description>
        <time_frame>15 to 36 months post-vaccination</time_frame>
        <population>Per protocol population who were quantiferon negative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Vaccine</title>
            <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.</title>
          <description>The number (percentage) of infants with QuantiFERON conversions at any time on the study were summarized by treatment group.</description>
          <population>Per protocol population who were quantiferon negative at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1398"/>
                <count group_id="O2" value="1394"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Two subjects within the control group were randomized but did not receive control vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Investigational Vaccine</title>
          <description>MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="1399"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intestinal functional disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1399"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="1399"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1399"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="101" subjects_affected="91" subjects_at_risk="1399"/>
                <counts group_id="E2" events="94" subjects_affected="88" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="1399"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="1399"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonia measles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1399"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1399"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1399"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1399"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental drug intake by child</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonitis chemical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1399"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HIV test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Kwashiorkor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1399"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1319" subjects_at_risk="1399"/>
                <counts group_id="E2" subjects_affected="1064" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="308" subjects_affected="259" subjects_at_risk="1399"/>
                <counts group_id="E2" events="245" subjects_affected="216" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="240" subjects_affected="191" subjects_at_risk="1399"/>
                <counts group_id="E2" events="199" subjects_affected="157" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1183" subjects_affected="1121" subjects_at_risk="1399"/>
                <counts group_id="E2" events="459" subjects_affected="446" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Injection site exfoliation</sub_title>
                <counts group_id="E1" events="143" subjects_affected="143" subjects_at_risk="1399"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="421" subjects_affected="363" subjects_at_risk="1399"/>
                <counts group_id="E2" events="175" subjects_affected="154" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1146" subjects_affected="1050" subjects_at_risk="1399"/>
                <counts group_id="E2" events="273" subjects_affected="267" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="561" subjects_affected="473" subjects_at_risk="1399"/>
                <counts group_id="E2" events="279" subjects_affected="222" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="659" subjects_affected="523" subjects_at_risk="1399"/>
                <counts group_id="E2" events="553" subjects_affected="431" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="449" subjects_affected="372" subjects_at_risk="1399"/>
                <counts group_id="E2" events="323" subjects_affected="271" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="67" subjects_affected="65" subjects_at_risk="1399"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="192" subjects_affected="183" subjects_at_risk="1399"/>
                <counts group_id="E2" events="180" subjects_affected="172" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="389" subjects_affected="321" subjects_at_risk="1399"/>
                <counts group_id="E2" events="357" subjects_affected="285" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="478" subjects_affected="376" subjects_at_risk="1399"/>
                <counts group_id="E2" events="419" subjects_affected="324" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="368" subjects_affected="295" subjects_at_risk="1399"/>
                <counts group_id="E2" events="296" subjects_affected="237" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="513" subjects_affected="398" subjects_at_risk="1399"/>
                <counts group_id="E2" events="447" subjects_affected="359" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restrictions on the PI include submission of study data as an Investigator’s Brochure prior to publication, sponsor’s review (for a period of 60-180 days from the time submission to the sponsor for review), correction of factual errors, accommodation of reasonable comments of sponsor relating to regulatory submissions/interpretation of the Study Data (including assertion of safety and efficacy).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard Landry</name_or_title>
      <organization>Aeras</organization>
      <phone>301-547-2919</phone>
      <email>blandry@aeras.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

